Avita Medical (ASX:AVH) said the Centers for Medicare & Medicaid Services (CMS) finalized national physician valuations for skin cell suspension autograft procedures performed using RECELL under the calendar year 2027 Medicare Physician Fee Schedule, according to a Friday Australian bourse filing.
The company said the national payment framework includes simplified billing codes for RECELL procedures in 2027.
AVITA's shares rose 2% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments